Abstract Rett syndrome is a childhood neurodevelopmental disorder caused by mutations in the gene encoding for methyl-CpG-binding protein (MeCP2). Neuropathological studies in patients with Rett syndrome and in MeCP2 mutant models have shown reduced dendritic arborization and abnormal neuronal packing. We have previously shown that Cerebrolysin (CBL), a neurotrophic peptide mixture, ameliorates the synaptic and dendritic pathology in models of aging and neurodegeneration. This study aimed to determine whether CBL was capable of reducing behavioral and neuronal alterations in Mecp2 308/Y mutant mice. Two sets of experiments were performed, the Wrst with 4-month-old male Mecp2 308/Y mutant mice treated with CBL or vehicle for 3 months (Group A) and the second with 1-month-old mice treated for 6 months (Group B). Behavioral analysis showed improved motor performance with CBL in Group A and a trend toward improvement in Group B. Consistent with behavioral Wndings, neuropathological analysis of the basal ganglia showed amelioration of dendritic simpliWcation in CBL-treated Mecp2 308/Y mutant mice. CBL treatment also ameliorated dendritic pathology and neuronal loss in the hippocampus and neocortex in Mecp2 308/Y mutant mice. In conclusion, this study demonstrates that CBL promotes recovery of dendritic and neuronal damage and behavioral improvements in young adult Mecp2 308/Y mutant mice and suggests that CBL may have neurotrophic eVects in this model. These Wndings support the possibility that CBL may have beneWcial eVects in the management of Rett syndrome.
Introduction
Rett syndrome is a childhood neurodevelopmental disorder characterized by normal early development followed by gait abnormalities, seizures and mental retardation. It is an X-linked disorder aVecting 1 in 15,000 female children and is caused by sporadic loss-of-function mutations of the gene encoding the transcriptional repressor methyl-CpGbinding protein (MECP2) [2, 3, 62] . Since this gene is located on the X-chromosome, Rett syndrome in its classic form only appears in girls, in males symptoms are more severe and usually lethal [8, 61] . A large number of mutations in the Mecp2 gene and X-chromosome inactivation patterns lead to a broad phenotypic spectrum [20, 47] .
Classic Rett syndrome Wrst appears after 6-18 months of apparently normal development when girls begin to regress intellectually in a predictable pattern [28] . Neuropathological studies have shown reduced brain size with decreased dendritic arborization and synaptic formation in the frontal, motor and temporal cortices [4, 6] . There is also increased neuronal packing density of small neurons and reduced expression of the dendritic protein-MAP2 [29] . The synapto-dendritic arbor of pyramidal neurons in the cortex appears to be selectively damaged, while calbindinexpressing interneurons are preserved. Alterations in cholinergic, dopaminergic and serotonin systems have also been reported [44] .
Supporting a role for Mecp2 in the pathogenesis of Rett syndrome, previous studies have shown that male transgenic mice expressing a targeted truncated Mecp2 (premature stop codon after codon 308) develop progressive neurological alterations beginning at 6 weeks that include tremor, motor impairment as assessed by pole test, hypoactivity and increased anxiety by 8 months mutant mice appear disheveled and are prone to seizures [38, 56] . The brains of the Mecp2 308/y mutant mice show increased levels of acetylated histone 3 and expression of the c-terminus truncated Mecp2; however, no conclusive neuropathological features have been described in this model. The Mecp2 308/Y model might mimic the behavioral symptoms of patients with Rett syndrome closer than mouse models carrying null mutations [9, 19] . Though is important to remember that no animal model of a human disorder can completely mimic the condition seen in humans and that the neuropathology seen in models may be more subtle than that found in humans; together these Rett mice models can, in addition to mimicking behavioral characteristics of Rett such as deWcits in locomotion [56] , provide important information regarding the neuropathology of Rett syndrome including altered hippocampal and amygdala volumes [58] and altered post-synaptic density length in the hippocampus [39] .
Although considerable progress has been made at understanding the genetics and molecular mechanisms of Rett syndrome and the eVects of mutations in Mecp2, no therapies are currently available.
Cerebrolysin (CBL) is a brain-derived peptide preparation produced by a standardized enzymatic breakdown of puriWed brain proteins and consists of low-molecular weight neuropeptides and free amino acids. We have previously shown that CBL ameliorates the synaptic and dendritic pathology in models of aging and neurodegeneration [23, 24, 35, [49] [50] [51] [52] 64] . CBL has been shown to display nerve growth factor (NGF)-like eVects on cholinergic neurons [55] and to protect synapses and dendrites by blocking glycogen synthase kinase3 (GSK3 ) and cyclin-dependent kinase 5 (CDK5) hyperactivation [54] . Recent studies have shown that CBL reduces the memory deWcits in patients with dementia [1, 40, 63] and an open-pilot trial [16] in nine female Rett syndrome patients (2-7 years) showed that CBL normalized the electroencephalograph parameters, decreased seizures and improved behavioral and motor function.
Taken together these studies suggest that CBL may have beneWcial eVects in Rett syndrome by ameliorating the synaptic and dendritic pathology. In this context, and to investigate the potential inXuence of CBL on the pathogenesis of Rett-like phenotype, young and mature male Mecp2 308/Y mice were treated with CBL and behavior and neuropathological studies were performed (Fig. 1) . The Wndings suggest that CBL may help to ameliorate the pathological progression of Rett syndrome and therefore may have beneWcial eVects not only in neurodegenerative disorders such as Alzheimer's disease but also in neurodevelopmental disorders such as Rett syndrome.
Materials and methods

Breeding and maintenance of Mecp2
308/Y mouse model Breeding pairs of the Mecp2 308/Y mouse model were obtained from The Jackson Laboratory, Bar Harbor/ME. This model was selected because it has previously been shown to reproduce some aspects of the behavioral alterations in Rett syndrome [56, 57] . Female mutant homozygous mice die at a very young age and heterozygous females display an unbalanced pattern of X-chromosome inactivation which favors the expression of the wild-type allele and results in a high degree of phenotypic variability [66] , in an eVort to avoid these complications male mutant mice were used for these experiments. Young mutant female heterozygous mice and wild-type male littermates were bred over several generations to obtain a total of 48 male Mecp2 308/Y mutant mice. A subset (n = 8) of wild-type male mice were used as controls. Mutant oVspring were identiWed by PCR analysis of tail DNA. BrieXy, genomic DNA was extracted as previously described [37] and ampliWed 308/Y (Premature stop after codon 308) mutant mice, previously shown to display some behavioral characteristics associated with Rett syndrome [40] were obtained from the Jackson Laboratory and were divided into two experimental groups, diVering in their length of treatment with Cerebrolysin. Group A mice were treated from 4 till 7 months of age with either Cerebrolysin (5 ml/ kg, n = 12) or vehicle (saline, n = 12). Group B mice were treated from 1 month of age till 7 months with either Cerebrolysin (5 ml/kg, n = 12) or vehicle (saline, n = 12). At 7 months mice were analyzed behaviorally and then for neuropathology in 30 cycles (93°C £ 30 s, 49°C £ 30 s, 72°C £ 1 min) with a Wnal extension at 72°C £ 5 min.
Cerebrolysin treatment
In order to assess possible beneWcial eVects of CBL on behavioral and neuronal alterations in young and mature Mecp2 308/Y mutant mice, two sets of experiments were performed. For the Wrst, a total of 24 (4-month-old) male Mecp2 308/Y mutant mice were treated for 3 months with CBL (n = 12; 5 ml/kg) or vehicle (n = 12) (Group A) (Fig. 1) . For the second set, a total of 24 (1-month-old) male Mecp2 308/Y mutant mice were treated for 6 months with CBL (n = 12; 5 ml/kg) or vehicle (n = 12) (Group B) (Fig. 1) . CBL (and vehicle) were administered via i.p injection.
The two groups were designed to enable a comparison of the eVects of Cerebrolysin when given as a therapeutic measure, once the disease has become established (Group A, treatment from 4 till 7 months) versus its eVects when administered as an early intervention prior to the frank onset of the disease (Group B, treatment from 1 to 7 months).
At the end of the treatment period, mice were tested behaviorally in the open Weld and pole test. These tests were designed to assess the motor function of the mice. The open-Weld test is the most standardized measure of general motor function [11] , while the pole test is a well-documented test used to assess basal ganglia-related movement in mice [12, 13, 27, 36, 45, 46] .
In order to assess the baseline levels of neuropathology, groups (n = 3) of untreated Mecp2 308/Y mutant mice were killed at 1, 4 and 7 months of age. These animals were compared to age-matched wild-type controls.
Behavioral analysis
For the open Weld, spontaneous activity was measured in Plexiglas cages (42 £ 22 £ 20 cm) placed into frames (25.5 £ 47 cm) mounted with two levels of photocell beams at 2 and 7 cm above the bottom of the cage (San Diego Instruments, 308/Y mutant mice. Cerebrolysin treatment in Group A increased total, rearing and lateral activity to levels comparable with wild-type controls (P < 0.05). Rearing activity was also reduced in Group B vehicle-treated
Mecp2
308/Y mutant mice in comparison to wild-type controls; Cerebrolysin treatment increased rearing activity in these mice to a level comparable to wild-type control mice. Analysis of the time spent in the centre of the cage versus time spent at the perimeter (d-f) showed no diVerences between wild-type controls and vehicle-or Cerebrolysintreated Mecp2 308/Y mutant mice. *indicates a signiWcant diVerence between vehicle-treated Mecp2 308/Y mutant mice (n = 12) and wild-type controls (n = 8) (P < 0.05, by one-way ANOVA and post hoc Fisher) **indicates a signiWcant diVerence between Cerebrolysin-treated Mecp2 308/Y mutant mice (n = 12) and wild-type controls (n = 8) (P < 0.05, by one-way ANOVA and post hoc Fisher) San Diego, CA). These two sets of beams allow for the recording of both horizontal (locomotion) and vertical (rearing) behavior. SpeciWc variables derived included horizontal activity, vertical activity, total distance traversed, total number of movements and time spent in the center versus time spent in the perimeter of the cage (thigmotaxis). Mice were tested for 5 min as this is usually suYcient to evaluate gross abnormalities in locomotion [11] .
For the pole test, animals were placed head upward on top of a vertical wooden pole 50 cm long (1 cm in diameter). The base of the pole was placed in the home cage. When placed on the pole, animals orient themselves downward and descend the length of the pole back into their home cage. Groups of mice received 2 days of training that consisted of Wve trials for each session. On the test day, animals received Wve trials, time to orient downward (T-turn), time to travel down the pole (T-travel) and total time to descend (T-total) were measured.
Tissue processing and analysis of neurodegeneration Following NIH guidelines for the humane treatment of animals, under anesthesia mice were killed and brains removed. The right hemibrain was immersion-Wxed in 4% paraformaldehyde in pH 7.4 PBS and serially sectioned at 40 m with the Vibratome (Leica, DeerWeld, IL) for subsequent analysis of neurodegeneration. The left hemibrain was kept at ¡80°C. To investigate the eVects of CBL in Mecp2 308/Y mutant mice, vibratome sections were immunolabeled overnight with antibodies against the neuronal marker NeuN (1:1,000, Chemicon) and the dentritic marker MAP2 (1:250, Chemicon), followed by incubation with species-appropriate secondary antibodies (1:200, Vector Laboratories). Sections were transferred to SuperFrost slides (Fisher ScientiWc, Tustin, CA) and mounted under glass coverslips with anti-fading media (Vector Laboratories). The immunolabeled blind-coded sections were analyzed with the laser scanning confocal microscope (LSCM) (MRC1024, BioRad) to evaluate the area of the neuropil covered by MAP2 immunoreactive dendrites in the basal ganglia, frontal cortex, dentate gyrus, CA3 and CA1 regions of the hippocampus. Stereological analysis was also conducted using the Stereo Investigator software package (MBF Biosciences), as previously described [32] to examine the neuronal density in the basal ganglia, frontal cortex (layers II/III, 3 sections, 4 Welds per section) and dentate gyrus, CA3 and CA1 regions of the hippocampus, neurons were determined by NeuN immunoreactivity, this measure is an estimate of total cell number.
The frontal cortex and hippocampus were investigated on the basis of previous studies reporting dendritic abnormalities in the neocortex [29, 30] and impaired learning, memory and post-synaptic density morphology [39] , the basal ganglia were chosen as motor activity linked to basal ganglia function was being assessed.
Western blot analysis
Protein levels of acetylated histone H3 and total H3 histone in Mecp2 308/Y mutant mice were analyzed by immunoblot. Brain homogenates were obtained as previously described [53] . Twenty micrograms of total protein per mouse were loaded onto 10% Bis-Tris (Invitrogen) SDS-PAGE gels, transferred onto Immobilon membranes, incubated with antibodies against anti-acetyl-histone H3 rabbit polyclonal (1:1,000, Upstate Biotechnology) and anti-histone H3 mouse monoclonal antibody (1:1,000, Upstate Biotechnology). After overnight incubation with primary antibodies, membranes were incubated in appropriate secondary antibodies, reacted with ECL and developed on a VersaDoc gel-imaging machine (Bio-Rad, Hercules, CA). Anti-betaactin (1:1,000, Sigma) was used to conWrm equal loading.
Statistical methods
DiVerences between groups were tested using one and two factor ANOVA with Fisher PLSD posthoc tests. Additional preliminary analysis between control and treated groups was by unpaired, two-tailed, Student's t test. All the results are expressed as mean § SEM.
Results
Cerebrolysin eVects on behavioral performance in mature and young Mecp2 mutant mice Previous studies have shown that Mecp2 mutant mice older than 6 weeks display alterations in the open Weld and pole test [19, 56] . Compared to age-matched wild-type controls, vehicle-treated Mecp2 308/y mutant mice in Group A displayed decreased total, rearing and lateral activity (Fig. 2a-c) . CBL treatment of Group A Mecp2 308/y mutant mice increased total, rearing and lateral activity in comparison to vehicle-treated Group A Mecp2 308/y mutant mice and to a level comparable to wild-type controls (Fig. 2a-c) . In Group B, where treatment was started at a younger age, there was a trend toward decreased total (P = 0.3), rearing (P = 0.09) and lateral (P = 0.08) activity in vehicle-treated Mecp2 308/y mutant mice in comparison to wild-type controls and an amelioration of this phenotype with CBL treatment (Fig. 2a-c) . No signiWcant diVerences in thigmotaxis 
where observed between wild type and vehicle-or CBLtreated Mecp2 308/Y mutant mice (Fig. 2d-f ). In the pole test, vehicle-treated Mecp2 308/Y mutant mice from both Groups A and B displayed signiWcantly longer T-total times in comparison to age-matched wild-type controls (P < 0.05). There were no signiWcant diVerences in T-Total upon CBL treatment, though a trend toward decreased T-Total (P = 0.08) was observed in Group A Mecp2 308/Y mutant mice in comparison to vehicle-treated Mecp2 308/Y mutant mice (Fig. 3a) . T-Turn was signiWcantly increased in both Groups A and B vehicle-treated Mecp2 308/Y mutant mice in comparison to wild-type controls. There were no signiWcant diVerences in T-Turn upon CBL treatment, though a trend toward decreased T-Turn (P = 0.08) was observed in Group A Mecp2 308/Y mutant mice in comparison to vehicle-treated Mecp2 308/Y mutant mice (Fig. 3b) . Vehicle-treated Mecp2 308/Y mutant mice from both Groups A and B displayed signiWcantly increased T-travel times in comparison to wild-type controls, CBL treatment signiWcantly lowered T-travel time in both Groups A and B in comparison to vehicle-treated Mecp2 308/Y mutant mice (Fig. 3c) .
Cerebrolysin eVects on patterns of neurodegeneration in mature and young Mecp2 308/y mutant mice
In order to establish a baseline for the neuropathology observed in the Mecp2 308/y mutant mice, untreated Mecp2 308/y mutant mice were killed at 1, 4 and 7 months and compared to age-matched wild-type mice. No real diVerence in dendritic complexity in the basal ganglia, as evidenced by MAP2 immunoreactivity, was evident between wild-type mice and untreated Mecp2 308/y mutant mice at 1 month of age (Fig. 4a, b) . By 4 months of age the untreated Mecp2 308/y mutant mice begin to show a reduction in dendritic complexity in comparison to age-matched wild-type mice (Fig. 4c, d ), this becomes increasing marked at 7 months of age (Fig. 4e, f) . Similar results were observed in the neocortex and hippocampus (data not shown).
Consistent with behavioral data, neuropathological analysis of the basal ganglia at 7 months showed a decrease in dendritic complexity as evidenced by MAP2 immunoreactivity in vehicle-treated Mecp2 308/Y mice in comparison to age-matched wild-type controls in both Groups A and Group B (Fig. 5a, b) . CBL treatment signiWcantly ameliorated this dendritic pathology in Mecp2 308/Y mutant mice in comparison to vehicle-treated Mecp2 308/Y mice (Fig. 5c, d ). Levels of MAP2 immunoreactivity in CBL-treated Mecp2 308/Y mutant mice were comparable to those seen in wild-type mice (Fig. 5d) .
Stereological analysis of neuronal density in the basal ganglia, as evidenced by NeuN immunoreactivity, revealed no signiWcant diVerences in NeuN immunoreactivity between wild type and vehicle-or CBL-treated Mecp2 308/Y mutant mice (Fig. 5e-h) .
In order to further characterize the patterns of neurodegeneration and response to CBL, dendritic pathology and neuronal number were analyzed in the hippocampus and neocortex. Compared to age-matched wild-type controls, vehicle-treated Mecp2 308/y mutant mice displayed a signiWcant decrease in the levels of MAP2 immunoreactivity in pyramidal neurons in the CA3 region of the hippocampus (Figs. 6d-h, 7a) . The dendritic arbor of these neurons was considerably simpliWed and in many instances was tortuous and irregular (arrows in Fig. 6k ). CBL treatment ameliorated the dendritic pathology in the hippocampus and increased the levels of MAP2 immunoreactivity in the CA3 region in both Groups A and B, (Figs. 6e, f, h, 7a) . In comparison to age-matched wild-type controls, the dentate gyrus of Group A vehicle-treated Mecp2 308/y mutant mice also showed a signiWcant loss of MAP2 immunoreactivity (Fig. 7b) . CBL administration ameliorated this loss, with levels of MAP2 immunoreactivity in the dentate gyrus of Group A CBL-treated Mecp2 308/y mutant mice being comparable to those observed in wild-type controls (Fig. 7b) . No signiWcant diVerences in MAP2 levels were observed in the CA1 between wild type and vehicle-or CBL-treated Mecp2 308/Y mutant mice (Figs. 6m-o, 7c ). Stereological analysis of pyramidal neurons with the antibody against NeuN, showed a reduction in NeuNimmunoreactive cells in hippocampal region CA3 of Group A and Group B vehicle-treated Mecp2 308/y mutant mice in comparison to wild-type controls (Fig. 7d) . CBL treatment signiWcantly ameliorated this loss in both Groups A and Group B mice with a larger proportion of NeuN-immunoreactive neurons in CBL-treated Mecp2 308/y mutant mice, with the number of NeuN-immunoreactive cells in these mice being comparable to that in wild-type controls (Fig. 7d) . Compared to age-matched wild-type controls, Group A and Group B vehicle-treated Mecp2 308/y mutant mice also displayed a reduced number of NeuN-immunoreactive cells in the dentate gyrus. CBL treatment ameliorated this loss in Group A Mecp2 308/y mutant mice (Fig. 7e) , with a similar trend observed in Group B CBL-treated Mecp2 (Fig. 7f) . The neocortex of Group A and Group B vehicle-treated Mecp2 308/y mutant mice showed a moderate loss of MAP2 immunoreactivity in comparison to wild-type controls (Fig. 8a, b) . CBL treatment signiWcantly ameliorated this loss of MAP2 immunoreactivity in Group A Mecp2 308/y mutant mice in comparison to vehicle-treated Mecp2 308/y mutant mice (Fig. 8c, d) and to a lesser extent in CBLtreated Group B Mecp2 308/y mutant mice (Fig. 8d) . In comparison to wild-type control mice, NeuN immunoreactivity was signiWcantly reduced in the neocortex of Group A and Group B vehicle-treated Mecp2 308/y mutant mice (Fig. 8e, f) . CBL treatment signiWcantly increased the proportion of NeuN-immunoreactive neurons in Group A Mecp2 308/y mutant mice (Fig. 8g, h ) and to a lesser extent in Group B mice in comparison to vehicle-treated Mecp2 308/y mutant mice.
Cerebrolysin eVects on H3 histone acetylation
Mecp2 is proposed to function as a global transcriptional repressor by binding methylated DNA and interacting with histone de-acetylase-containing complexes that remodel the chromatin structure to repress gene transcription [15, 33, [41] [42] [43] . Previous studies with Mecp2 308/Y mutant mice have shown that these mice display a hyperacetylation of histone H3 [56] . In an eVort to pinpoint the mechanism by which CBL exerts its eVect we sought to determine if CBL had any possible eVect on Mecp2-regulated H3 histone acetylation. Consistent with the previous studies on these mice [42] , compared to wild-type controls, levels of acetylated H3 were higher in Mecp2 308/Y mutant mice (Fig. 9a) . Interestingly, no eVects of CBL administration on levels of H3 acetylation were observed (Fig. 9a) . Western blot analysis of total H3 histone levels (Fig. 9b) revealed no diVerences between wild type and vehicle-or CBL-treated Mecp2 308/Y mutant mice. These results indicate that the beneWcial eVects of CBL seen in this study are independent of the known transcription-regulating eVects of Mecp2 and are suggest that they likely to be related to the previously reported neurotrophic action of CBL [14, 21, 23, 26, 55] . [56] and are reminiscent of the behavioral disturbances in patients with Rett syndrome [31] . Consistent with these improvements, neuropathological examination of the basal ganglia in these mice found that CBL administration ameliorated the dendritic simpliWcation observed in the Mecp2 308/Y mice. Moreover, we found that CBL treatment ameliorated the extensive dendritic damage and neuronal loss observed in pyramidal neurons in the CA3 region of the hippocampus and in the neocortex of vehicle-treated Mecp2 308/Y mutant mice, such that levels of MAP2 and NeuN immunoreactivity in CBL-treated Mecp2 308/Y mutant mice were comparable to those seen in wild-type mice. These results are consistent with the previous studies that have reported impaired learning and memory and neuropathological alterations in the hippocampus of Mecp2 308/Y mutant mice [39] and dendritic abnormalities in the neocortex of Rett patients [29, 30] and suggest that CBL may have a beneWcial eVect in these regions. It is unclear why there are such diVerences between the diVerent hippocampal subWelds; we would speculate that it may be related to the fact that diVerent subWelds arise during diVerent periods of development and express diVerent macromolecules [17, 60] ; any insult or gene eVect occurring during neurodevelopment may only aVect a particular subWeld and its connectivity. In the adult, the subWelds receive aVerent and eVerent connections from diVerent regions; these connections may also be diVerentially susceptible in Rett syndrome and in turn to treatment with CBL.
The eVects of CBL in ameliorating the behavioral alterations in the Mecp2 308/Y mutant mice may be related to its ability to promote dendritic regeneration. In Rett syndrome, a decreased number of dendritic spines are observed in neocortical areas [7] and neurons in the frontal, motor and temporal cortex show shortened basal and apical dendrites [4, 6] . These brain areas are responsible for some of the signiWcant motor and behavioural symptoms observed in Rett syndrome [5] . A temporal correlation exists between the time point of normal maturation of layers III and V, when projection and association circuits of these layers are organized [48] , and the observation of clinical deWcits in Rett syndrome. These manifest as motor delays and emotional instability [5] and occur at the age of 1-3 years [31] . This observation suggests a possible relationship between the failure of the dendritic arborisation and the apparent failure of cortical processing leading to functional deWcits [5] . In addition to the morphological abnormalities noted in the Rett dendrites, biochemical changes such as a reduction in the expression of the dendritic marker MAP2 have also been reported in Rett patients [29] . Dendritic changes are also a consistent feature in diseases with mental retardation, such as Down syndrome [59] or fragile X syndrome [10] .
The eVects of CBL on dendritic arborisation have been investigated in a chronic low serum cell stress model [23] . After 4 days in cell culture, quantiWcation of spontaneous outgrowth of embryonic chicken telencephalon neurons demonstrated an outgrowth promoting eVect of CBL. In contrast to the observed neuronal degeneration after eight days in cells treated with a synthetic amino acid solution, CBL-treated cells presented a well-diVerentiated neuronal network that was more pronounced than those seen in control cultures treated with brain-derived neurotrophic factor (BDNF) or serum supplementation. These results suggest a neurotrophic role of CBL, which may in turn be due to the stabilizing eVect of CBL on the microtubule-associated protein MAP2.
Consistent with its role in promoting dendritic network formation, CBL has been shown to increase, in a dosedependent manner, levels of MAP2 expression in models of excitotoxicity [25, 26] . The exact mechanism by which CBL exerts its eVect on MAP2 remains unclear though a recent study found that CBL protects against loss of MAP2 in translation-inhibited cell cultures treated with cycloheximide independently from de novo synthesis [65] .
It is worth noting that the beneWcial eVects of CBL in the Mecp2 308/Y mutant model were consistently more prominent in Group A (mature mice, 4-month-old, treated for 3 months) in comparison to mice in Group B (young mice, 1-month-old, treated for 6 months). It is interesting to note that at 1 month of age (when treatment began for Group B mice) there did not appear to be a diVerence in dendritic complexity between the Mecp2 308/Y mutant mice and age-matched wild-type control. Loss of dendritic complexity became more evident as the Mecp2 308/Y mutant mice aged, being noticeable at 4 months and more so at 7 months, the age bracket at which CBL seem to have exerted a greater eVect. This feature of the results may suggest a possible therapeutic window for the eVects of CBL and could indicate that it has a trophic rather than preventative mode of action. Consistent with this hypothesis, CBL has been reported to have neurotrophic eVects in vitro on cultured neurons from chicken embryos [40] and synaptotrophic eVects on neuronal cells [34] . Consistent with in vitro data, in vivo demonstration of the neurotrophic eVects of CBL were observed in studies examining cell death in rat spinal motoneurons following avulsion of the ventral spinal roots [21, 22] . Though the molecular mediators of the neurotrophic eVect of CBL remain to be deWnitively determined, CBL had been reported to reduce levels of CDK5 and GSK3beta [53] , and this may be related to the beneWcial eVects of CBL on neuronal survival and its anti-apoptotic eVects [24] . This is consistent with the Wndings that CBL has no eVect on histone acetylation, as had this been the case it would have aVected both groups equally.
The neuropeptide mixture Cerebrolysin is a well-established compound used in the management of cognitive alterations in patients with dementia [1, 40, 63] and both in vitro and in vivo studies have shown that it has neurotrophic eVects and promotes synaptic and neuronal plasticity [18, 24, [49] [50] [51] and cytoskeletal stability [65] . The results from this study suggest that in addition to its documented beneWcial eVects in neurodegenerative conditions such as Alzheimer's disease it may also have potential as a treatment of neurodevelopmental disorders such as Rett syndrome.
